Back

PCSK9 Inhibitors: deep dive into guidelines and clinical data

9 November 2019 (12:40 - 13:05)
Organised by:
Congress Presentation Part of: Understanding PCSK9 Inhibitors: what, when and why? PCSK9-Antagonists ESC Premium Access ESC Asia with APSC & AFC

About the speaker

Photo
Associate Professor Karam Kostner

University of Queensland, Brisbane (Australia)

3 More presentations in this session

Presentation thumbnail
Welcome and opening remarks: confronting the burden of LDL-C in Asia
Associate Professor J. Tan (Singapore, SG)
Slides Video
Presentation thumbnail
Treating patients in the real world
Professor S. Uemura (Kurashiki, JP)
Video
Presentation thumbnail
Questions and answers and closing remarks
Associate Professor J. Tan (Singapore, SG)
Video

Access the full session

Session thumbnail
Understanding PCSK9 Inhibitors: what, when and why?

The Event

Event poster

ESC Asia with APSC & AFC

9 November 2019 12:40 CET
You may be interested in
thumbnail
Webinar
LDL-C reduction postACS: strike early and strike strong
15 November 2021
thumbnail
Congress Presentation
PCSK9 inhibitors and incidence of arrhythmias in clinical practice: a phase IV multicentric study
18 April 2023
thumbnail
Congress Presentation
Oral PCSK9 inhibitors
30 August 2026
thumbnail
Webinar
Injectable therapies for cardiovascular disease: optimising their use in practice - experiences from the UK and Italy
18 March 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources